Bittersweet Comments from Needham & Co. regarding Sagent Pharmaceuticals (SGNT)
Tweet Send to a FriendGet Alerts SGNT Hot Sheet
Price: $17.75 +2.54%
Rating Summary:
6 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 26 | New: 12
Rating Summary:
6 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 26 | New: 12
Trade SGNT Now!
Needham & Company analysts maintained a Buy rating on Sagent Pharmaceuticals (NASDAQ: SGNT) but cut their price target to $20.00 (from $25.00).
The good news is that Sagent Pharmaceuticals' model continues to “work”, said analyst Elliot Wilbur. “SGNT delivered strong topline performance in 2Q12, margins continue to expand and significant value continues to accrue in its ANDA pipeline, ensuring strong future growth prospects.”
“The bad news is that we think SGNT remains its own worst enemy with respect to the establishment and achievement of short-tem performance expectations, and management credibility likely has been dealt a significant blow following rather marked reduction in 2012 top- and bottom-line expectations,” warned Wilbur.
Needham & Company's $20 target reflects a 15.0X P/E applied to lowered 2014E EPS of $1.34 (was $1.76).
For an analyst ratings summary and ratings history on Sagent Pharmaceuticals click here. For more ratings news on Sagent Pharmaceuticals click here.
Shares of Sagent Pharmaceuticals closed at $13.25 yesterday, with a 52 week range of $13.14-$26.74.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The good news is that Sagent Pharmaceuticals' model continues to “work”, said analyst Elliot Wilbur. “SGNT delivered strong topline performance in 2Q12, margins continue to expand and significant value continues to accrue in its ANDA pipeline, ensuring strong future growth prospects.”
“The bad news is that we think SGNT remains its own worst enemy with respect to the establishment and achievement of short-tem performance expectations, and management credibility likely has been dealt a significant blow following rather marked reduction in 2012 top- and bottom-line expectations,” warned Wilbur.
Needham & Company's $20 target reflects a 15.0X P/E applied to lowered 2014E EPS of $1.34 (was $1.76).
For an analyst ratings summary and ratings history on Sagent Pharmaceuticals click here. For more ratings news on Sagent Pharmaceuticals click here.
Shares of Sagent Pharmaceuticals closed at $13.25 yesterday, with a 52 week range of $13.14-$26.74.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- Best Buy (BBY) Numbers Raised at Jefferies Post Q1
- Jefferies Raises Numbers on hhgregg (HGG), But Remains on Sidelines
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Needham & Company
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
